GSK Reports the Data from the P-III (FIRST-ENGOT-OV44) Study Evaluating Zejula and Jemperli in 1L Advanced Ovarian Cancer
Shots: GSK reported data from the P-III (FIRST-ENGOT-OV44)study
Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism
Shots: The P-II (ROXI-VTE-I) study assessed REGN9933 (IV) vs enoxaparin (QD) &...
Roche Reports the P-IIb (PADOVA) Trial Data of Prasinezumab for Early-Stage Parkinson’s Disease
Shots: The P-IIb (PADOVA) study assessed safety & efficacy of prasinezumab (15...
Merus Reports Dosing of First Patient in P-II Study Evaluating Petosemtamab in 3L+ mCRC
Shots: Merus reported the dosing of the first patient in its P-II study evaluating...
Merck Discontinues Clinical Development Programs Evaluating Vibostolimab and Favezelimab for Various Indications
Shots: Merck reported the discontinuation of the clinical development program ...
Regeneron Reports Data from P-III (QUASAR) Trial of Eylea HD (Aflibercept) in Patients with Macular Edema following Retinal Vein O...
Shots: The P-III QUASAR study of Eylea HD [Q8W, post 3 (n=293) or 5 (n=298) initia...
